This study is testing a new treatment called **sacituzumab tirumotecan** against chemotherapy for people with a specific type of lung cancer, called **non-small cell lung cancer (NSCLC)**. NSCLC is a type of cancer that starts in the lungs. The study includes people who have certain changes in their genes, like **EGFR mutations**. EGFR mutations are changes in a gene that can make cancer grow faster. The researchers want to see if sacituzumab tirumotecan helps people live longer without their cancer getting worse, compared to chemotherapy.

• The study involves multiple visits to the clinic.
• Participants might receive a new treatment that could work better than current options.
• Some risks may include side effects from the new treatment.

Participants need to have been treated before, but their cancer has worsened. They must have a certain health level and cannot have some other health problems like severe heart disease or active infections. If someone has a different type of lung cancer or hasn't tried some previous treatments, they might not qualify. This study offers a chance to try a new treatment that could potentially be more effective than current ones for certain gene changes in lung cancer.